Overview of rHGH therapy

January 14, 2015- Interviewed by Steven E. Greer, MD

We interviewed Dr. Shlomo Melmed, Director of the Clinical Research Institute and Dean of Faculty at Cedars Sinai Medical center in Los Angeles, about recombinant Human Growth Hormone (rHGH) therapies. Dr. Melmed writes the chapter on pituitary for Harrison’s Internal Medicine textbook, among other accomplishments.

We asked him whether exogenous HGH or IGF-1 causes cancer? Do they cause acromegaly? What is the federal law that is unique to HGH prescribing?

This entry was posted in Cedars Sinai, Diabetes and endocrinology. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *